The Quantellect read.As of Nov 19, 2026, 3 active firms cover Xeris Pharmaceuticals Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $13.33 sits 21% below the current $16.98. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.03 next quarter toward $0.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$13.33
-21.5% downside
Average target across 3 active firms as of Nov 19, 2026 vs $16.99 current
Highest Target$16.00
Average Target$13.33
Lowest Target$10.00
Detailed analyst forecasts for XERS
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate XERS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
XERS EPS & revenue forecast
EPS · NEXT QUARTER
$0.03
Range $0.02 – $0.04 · 2 analysts · +200% YoY
Next period, 2 analysts expect Xeris Pharmaceuticals Inc to earn $0.03 a share (range $0.02 – $0.04), versus $0.01 a year earlier. Full-year consensus is $-0.01, growing to $0.27 the year after.
REVENUE · NEXT QUARTER
$115.9M
Range $114.1M – $118.7M · 2 analysts · +39% YoY
Revenue is expected to reach $115.9M (range $114.1M – $118.7M), +39.5% year-over-year. Full-year consensus is $401.5M, rising to $526.6M next year.
Top analysts covering Xeris Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XERS.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
$12.00-29.3% to target
Overall win rate
61%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #124
Neutral
$8.00-52.9% to target
Overall win rate
50%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #217
Buy
$8.00-52.9% to target
Overall win rate
54%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$10.00-41.1% to target
Overall win rate
38%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #404
Buy
$21.00+23.6% to target
Overall win rate
35%
+ Follow
XERS stock forecast FAQ
What is XERS's average 12-month price target?+
The 3 active firms with a live target average $13.33 for Xeris Pharmaceuticals Inc over the next 12 months, ranging from a $16.00 high to a $10.00 low, as of Nov 19, 2026.
Is XERS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for XERS?+
The Street-high target is $16.00 (Leerink Partners), and the Street-low is $10.00 (HC Wainwright & Co.). The average of all 3 active-firm targets is $13.33.
How many active Wall Street firms cover XERS?+
3 active firms have a recognized rating on Xeris Pharmaceuticals Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering XERS?+
Among analysts who currently cover XERS, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy with a $12.00 target.
What is Xeris Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.03 per share (range $0.02 – $0.04) across 2 analysts. Full-year EPS is projected at $-0.01, rising to $0.27 the following year.
How much revenue is Xeris Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $115.9M (range $114.1M – $118.7M). Full-year revenue is projected at $401.5M, growing to $526.6M next year.
Have analysts been upgrading or downgrading XERS lately?+
As of Nov 19, 2026, 3 of 3 active firms rate XERS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XERS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.